Xu K, Ren X, Ju B, et al. - The present study was conducted to evaluate whether and how clinical markers combined with high-mobility group box 1 (HMGB1) polymorphisms to prognosticate the efficacy of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients. Researchers obtained clinical information of RA patients and HMGB1polymorphisms (rs4145277, rs2249825, rs1412125, and rs1045411) were examined. This analysis included a total of 252 patients, The outcomes of this study indicate that clinical markers and rs2249825 GG genotype can be applied to prognosticate poor csDMARDs outcome.